lifestyle spending accounts glp-1 prescriptions weight management reimbursement What is a Account (LSA)? Updated for 2026 Payer strategies for GLP-1 medications

available only through 503A compounding pharmacies under physician supervision Typical research dose range / 200-800 mcg/day subcutaneously, cycled 4-8 weeks Known lethal dose (LD50) / Not established in any species studied to date Rodent acute toxicity ceiling / No mortality observed at doses exceeding 10 mg/kg intraperitoneally Most reported excess-dose symptoms / Nausea, lightheadedness, flushing, injection-site irritation Organ toxicity at supratherapeutic doses / Not demonstrated in published preclinical literature Antidote availability / No specific antidote exists

Procedures may vary in jurisdictions where different requirements are imposed by law

The peptide has a simple structure just three amino acids (glycine, histidine, and lysine) bound to a copper(II) ion

Current evidence is strongest for mechanisms in cell culture rather than large-scale human efficacy studies